Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA4 | P22748 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.42 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494790 | 1.00 | CA1 (0.54) | CA1CA2CA4CA9JAK2 | |
| SCHEMBL2943387 | 1.00 | CA1 (0.54) | CA1CA2CA4CA9JAK2 | |
| SCHEMBL28078174 | 0.92 | CA1 (0.47) | CA1CA2CA4CA9JAK2 | |
| SCHEMBL28078178 | 0.92 | CA1 (0.47) | CA1CA2CA4CA9JAK2 | |
| SCHEMBL16583198 | 0.89 | STS (0.54) | CA1CA2CA4CA9JAK2 | |
| SCHEMBL4972391 | 0.89 | GPR119 (0.47) | CA1CA2CA4CA9JAK2 | |
| SCHEMBL7047899 | 0.88 | JAK2 (0.47) | CA1CA2CA4CA9JAK2 | |
| SCHEMBL779489 | 0.87 | NAMPT (0.48) | CA1CA2CA4CA9JAK2 | |
| SCHEMBL12090083 | 0.86 | JAK2 (0.46) | CA1CA2CA4CA9JAK2 | |
| SCHEMBL8112498 | 0.86 | GPR119 (0.52) | CA1CA2CA4CA9JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| US-12234225-B2 | IL-17 ligands and uses thereof | DICE ALPHA, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-113874080-B | IL-17A modulators and uses thereof | 戴斯阿尔法公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | DICE MOLECULES SV, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11447468-B2 | IL-17 ligands and uses thereof | DICE ALPHA, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| WO-2014052699-A9 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| EP-1408986-B1 | PROTEOMIMETIC COMPOUNDS AND METHODS | UNIV YALE (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7312246-B2 | Proteomimetic compounds and methods | YALE UNIVERSITY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1408986-A4 | PROTEOMIMETIC COMPOUNDS AND METHODS | UNIV YALE (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050215563-A1 | Proteomimetic compounds and methods | YALE UNIVERSITY | 2005-09-29 | — | — | US | disclosed |
| US-6858600-B2 | Proteomimetic compounds and methods | YALE UNIVERSITY (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1408986-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030008882-A1 | Proteomimetic compounds and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| WO-2002089738-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | IL17A, IL2, IL15 | CA1 3906/4885CA2 4622/4885CA4 4496/4885 |
| US-20030008882-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | CA1 2339/4885CA2 1760/4885CA4 3585/4885 |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | CA1 4140/4885CA2 2397/4885CA4 3992/4885 |
| US-11447468-B2 | IL-17 ligands and uses thereof | IL17A, IL2, IL15 | CA1 3906/4885CA2 4622/4885CA4 4496/4885 |
| US-12234225-B2 | IL-17 ligands and uses thereof | IL17A, IL2, IL15 | CA1 3906/4885CA2 4622/4885CA4 4496/4885 |
| US-20050215563-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | CA1 2339/4885CA2 1760/4885CA4 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.